Dosing & Uses
Colorectal Cancer
Pending FDA approval for previously treated metastatic colorectal cancer (CRC)
Next:
Pharmacology
Mechanism of Action
Oral, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities
Fruquintinib inhibits VEGF-induced phosphorylation of VEGFRs 1, 2, and 3, which may result in inhibition of migration, proliferation and survival of endothelial cells, micro-vessel formation, and tumor cell proliferation resulting in tumor cell death
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
